Nexalin Technology, Inc. (NASDAQ: NXL) has taken a significant step forward in digital brain health care with the launch of NeuroCare, an AI-based virtual clinic platform created in collaboration with the University of California, San Diego (UC San Diego). This development represents the initial phase of deploying Nexalin's comprehensive digital health ecosystem aimed at elevating patient accessibility, optimizing cost efficiency, and facilitating sustained monitoring and care by physicians across critical neurological conditions.
The partnership with UC San Diego reinforces and capitalizes on ongoing clinical research efforts. Patient enrollment is underway for trials assessing Nexalin's non-invasive Deep Intracranial Frequency Stimulation (DIFS), a proprietary neurostimulation therapy targeting key brain-health indications. This clinical evaluation simultaneously marks the commercial debut of Nexalin's Gen-3 HALO headset, a next-generation device enhancing the delivery of DIFS treatments in home environments.
The integration of the NeuroCare platform with the Gen-3 HALO headset is a pivotal feature enabling seamless remote management and real-time monitoring of therapy sessions. This setup affords patients the convenience of receiving frequency-based neurostimulation therapy at home while ensuring continuous clinical oversight.
Through NeuroCare, patients diagnosed with Alzheimer's disease and dementia, mood disorders such as depression and anxiety, as well as military-related neurological traumas including traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD), can engage with the HALO headset for non-invasive treatment. The platform's design emphasizes privacy and continuity of care, functioning under a subscription business model that supports sustainable revenues alongside long-term health outcomes.
Remote engagement with healthcare providers via NeuroCare removes the necessity for physical clinic visits, thereby reducing common access barriers such as waiting times and physician-related costs. Moreover, the platform minimizes treatment stigma by providing patients with a private, home-based therapy option. Physicians benefit from real-time data streams that enhance their capacity to monitor patient progress and adapt treatment plans accordingly.
Supporting the scientific foundation of Nexalin’s neurostimulation approach, recent peer-reviewed research has validated its proprietary technology across multiple neurological and psychiatric conditions. Notably, an October 2025 publication in the journal Radiology detailed that Nexalin's proprietary 15 milliamp (mA) Gen-2 Nexalin DIFS technology—which represents an advanced form of transcranial alternating current stimulation (tACS)—demonstrated measurable improvements in cognitive function and brain network connectivity among individuals with mild Alzheimer's disease.
This body of evidence underscores the therapeutic potential of Nexalin's technology and fuels confidence in the company’s continued clinical and commercial advancement. The launch of the NeuroCare platform alongside the Gen-3 HALO headset signifies Nexalin's strategic transition toward a fully integrated digital health model, aligning with broader trends toward remote patient care and personalized medicine.
In financial markets, Nexalin's shares experienced an uptick following this announcement, trading up 11.51% to $0.63 during premarket hours, illustrating positive investor reception. The company's commitment to innovation and clinical validation could play a significant role in its future trajectory within the digital neurotherapeutics space.